Author

Yves Théorêt

Centre Hospitalier Universitaire Sainte-JustineORCID 0000-0002-2353-860XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

C. Casini RaggiiD· 2 shared Marie-Agnès M’Callum· 2 shared Massimiliano PaganelliiD· 2 shared Quang Toan Pham· 2 shared Basma Benabdallah· 1 shared Chenicka Lyn Mangahas· 1 shared Christian M. BeausejouriD· 1 shared Denis CyriD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

C. Casini RaggiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringbioRxivPreprintOct 8, 2025

Off-the-Shelf Engineered Liver Tissue Reverses Acute Liver Failure Without Immunosuppression

C. Casini Raggi, Pascal Lapierre, Marie-Agnès M’Callum…·Massimiliano Paganelli

This paper describes engineered liver tissue that reverses acute liver failure in mice without immunosuppression, demonstrating potential for clinical translation.

DOI 10.1101/2025.10.08.680796

mouseorganoid / primary culture

𝕏 PostBluesky

GeneticsbioRxivPreprintOct 6, 2025

NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients

Quang Toan Pham, Farzaneh Tamnanloo, Marie-Agnès M’Callum…·Massimiliano Paganelli

This study identifies the minimal effective NTBC dose to prevent liver damage in HT1 using an in vitro model and validates it in 99 patients, while highlighting residual gene dysregulation linked to cancer risk.

DOI 10.1101/2025.10.06.680797

humanbulk RNA-seq

𝕏 PostBluesky